|Bid||49.17 x 800|
|Ask||50.75 x 900|
|Day's Range||49.56 - 52.89|
|52 Week Range||36.15 - 85.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||74.24|
\\- Strong induction of antibody and T cell responses in animal models\\- Protection of the lung, reduction of viral load in nose and throat in challenge studies\\- Favorable safety profile with no evidence of vaccine-enhanced diseaseTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 23, 2020 / CureVac N.
Regeneron Pharmaceuticals stock rose on positive data on its possible Covid-19 treatment, while shares of Moderna and CureVac stock rose as their possible Covid-19 vaccines made advances.
* Study conducted in Peru and Panama * Trial involves 690 participants, including older adults * Evaluation of safety, reactogenicity and immunogenicityTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 29, 2020 / CureVac N.
The German Federal Ministry of Education and Research notified CureVac (NASDAQ:CVAC) on Sept. 4 that it would get $299 million in support grants to help with its development of a novel coronavirus vaccine. This sounds like a good thing for CureVac stock, but what does it mean?Source: rafapress / Shutterstock.com After all, the German government could give it $2.99 billion, and that still doesn't guarantee that it will make it across the finish line with purchase orders in hand. As I write this, CureVac has been a public company for 34 days. In this time, CVAC stock's gained 237% from its IPO price of $16. Interestingly, it gained more than that in its first-day return. In fact, by its second day of trading, CVAC had made IPO investors an astounding 383% return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf you were smart, you took your profits. Why do I say this? They May All Strike OutMy wife, who doesn't pretend to be some science wonk, continues to wonder what will happen if a vaccine is never found. * 10 Education Stocks to Buy for the Fall School SeasonAfter all, scientists identified the human immunodeficiency virus (HIV) in 1984. Margaret Heckler, the U.S. Secretary of Health and Human Services at the time, boldly predicted that a vaccine would be ready for testing in 24 months. In the 36 years since Heckler's bold proclamation, 32 million people have died, and we're still waiting for an HIV vaccine. "Influenza is able to change itself from one year to the next, so the natural infection or immunization the previous year doesn't infect you the following year. HIV does that during a single infection," Pediatrician and infectious disease specialist, Paul Offit, told CNN in May. "It continues to mutate in you, so it's like you're infected with a thousand different HIV strands. (And) while it is mutating, it's also crippling your immune system."Admittedly, the novel coronavirus doesn't mutate rapidly, unlike HIV and malaria, and so the odds of scientists finding successful vaccines to use safely on humans is much higher."The coronavirus's sluggish pace of mutation is good news for us: A virus that evolved more rapidly would have a greater chance of outrunning any vaccines or drugs developed to counter it," Evolutionary virologist Dr. Edward Holmes stated Sept. 11 in The New York Times. "…To my knowledge, there is to date no evidence that SARS-CoV-2 has become more virulent or more lethal - nor, for that matter, that it has become less so." Britain's ExperienceSo, while finding a vaccine for Covid-19 appears to be an easier task than HIV, the spinal cord damage suffered by a patient in the AstraZeneca (NYSE:AZN) clinical trial in Britain suggests that an effective and safe vaccine is unlikely to be had before the end of the year. "The investigators [in the AstraZeneca trial] have inadvisedly been hyping their own vaccine," Vanderbilt University School of Medicine infectious disease specialist William Schaffner said recently. "The Oxford investigators were out there this summer saying, 'We're going to get there first.' But this is exactly the sort of reason … Dr. [Anthony] Fauci and the rest of us have been saying, 'You never know what will happen once you get into large-scale human trials.'"That's why CureVac continues to receive investor interest. You never know. All the trials currently in Phase 3 and 2 could fail while CureVac moves through Phase 2 and 3 with little or no issues. It could happen. But will it? What Happens to CureVac Stock If It Fails?At some point in the fourth quarter, CureVac will report its findings from its Phase 1 clinical trial. CureVac will use the results from its Phase 1 clinical trial to identify the optimal dose for its vaccine candidate. Once it knows this, it can start its Phase 2b study later in the year. CureVac will get $122 million of the $299 million by the end of 2020. It will get the rest in 2021. It's already entered negotiations with the EU to supply up to 405 million doses of its vaccine. So, things are moving along. My InvestorPlace colleague Josh Enomoto is cautiously optimistic about CureVac's chances."Potentially benefiting CureVac stock and its direct competitors are the many advantages of nucleic acid-based vaccines. At this juncture, the most critical are 'stimulation of innate immune response' and 'rapid and scalable' production," Enomoto stated on Sept. 9. "What could tip the scale in favor of CVAC is its experience working with coronaviruses (MERS in 2017). Additionally, the company claims it has the 'capability to manufacture mRNA-based vaccines in a huge scale.'" The Bottom LineAs they say, it's not where you start that counts, it's where you finish. In this biotech crapshoot, anything could happen. Will the $299 million make a difference to CureVac's vaccine development? You bet it will. Will it be what pushes CureVac to victory? I highly doubt it. As Josh also said, the Covid biotechs are off-the-charts volatile. Only bet on CureVac stock if you're confident you won't need the money you've bet on its success. And, yes, none of the current contenders may come up with a vaccine. If that happens, CVAC won't be trading at around $50 for very long. On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. Will Ashworth has written about investments full-time since 2008. Publications where he's appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Germany Makes a $299 Million Bet on CureVac appeared first on InvestorPlace.
Vaccines based on mRNA are among the leaders in the quest to end the Covid-19 pandemic, but that could just be the start for a technology also aiming at cancer and infectious diseases.
Ministry submits official notification of funding to CureVacGrant as part of special program to accelerate COVID-19 vaccine developmentTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 4, 2020 / CureVac N.
Pandemic vaccine plays have cooled off as of late. And that includes recent IPO CureVac (NASDAQ:CVAC). After going public last month at $16 per share, CureVac stock soared to prices topping $85 per share. But, in the past few weeks, as investors reassess upside potential, shares have pulled back, and now trade around $56 per share.Source: rafapress / Shutterstock.com The question is, "should you buy the pullback?" There are scores of vaccine contenders in this horse race. Some, like Moderna (NASDAQ:MRNA) remain the front-runners. Others, like iBio (NYSEAMERICAN:IBIO) and Inovio (NASDAQ:INO) have fallen fast behind.But CureVac? While not the strongest vaccine play out there, it does have its merits. Namely, the German-based company could have an edge when it comes to inking vaccine deals with European governments. Given that its likely multiple contenders will wind up selling vaccines in the global market, there's room for this company to succeed.InvestorPlace - Stock Market News, Stock Advice & Trading TipsYet, despite stronger prospects than many smaller vaccine plays, this remains a high-risk opportunity. With so much contingent on the company bringing a vaccine to market, shares will crater if it fails. * 9 Outbreak-Fueled Stocks to Buy This WeekSo, what's the play? Shares may be a great buy on the recent pullback - but tread carefully. For those interesting in high-risk plays, there's opportunity. But, otherwise, hold off for now. CureVac Stock and Vaccine Success OddsGiven that Moderna, AstraZeneca (NYSE:AZN), and Pfizer (NYSE:PFE) are much further down the pipeline when it comes to a vaccine candidate, what are the odds for this company?Not as bad as they seem at first glance. As I discussed above, CureVac may have a shot at securing vaccine deals in its home turf of Europe. In fact, deals are in motion. As InvestorPlace's Mark Hake wrote Aug. 26, the company is in advanced talks to sell 225 million doses to the European Commission. This proposed deal could also include a follow-on order of 180 million does.Multiply that by what rivals may charge for their vaccines, and that looks like big money, right? Well, unlike its rivals, this company plans to sell its vaccine (if approved) for between $3-$4 per dose. Yet, as Hake calculated, this could still mean billions in recurring revenue. Based on his numbers, shares could more than triple if it all works out.But, will it all work out? Possibly. European governments may prefer to go with a German provider than an American-based one. And, developing countries may prefer CureVac's low-cost option to what could be more expensive offerings from the main contenders.However, don't take this to mean success is a slam-dunk. For one, the company won't wrap up clinical trials under the fourth quarter of 2020. By that time, the front-runner candidates may already have regulatory approval.Secondly, does today's valuation take into account how the company plans to price its doses much lower than the competition? Low-dose prices may help CureVac secure more deals. But, investors may be plugging in levels of profitability that aren't possible unless the company sells its vaccine at prices on par with the others. What Else is on the Table?As I've discussed with other vaccine plays, I like to look at whatever non-pandemic catalysts are in the pipeline. In a worst-case scenario, other treatments/vaccines in development could help minimize downside if the coronavirus catalyst falls short.So, what's the case here with CureVac stock? Yes, the company has some other coals in the fire. As this commentator noted, along with its pandemic candidate, the company has three other mRNA candidates in Phase 1 testing. These consist of two cancer immunotherapies, along with a rabies vaccine.But, while this portfolio of candidates shows some promise, it doesn't hold a candle to Moderna's mRNA pipeline. The better-known pandemic play has much stronger candidates outside of coronavirus that could help minimize downside if its virus catalyst falls short.With this in mind, CureVac has more room to fall if its pandemic catalyst crashes and burns. If this happens, the stock will likely tumble toward its IPO price. In other words, a material amount of downside. Should You Buy, Sell, or Hold? It DependsWhat's the bottom line with CureVac? Are shares a buy? A sell? A stay-on-the-sidelines situation?It depends. If you have a high-risk appetite, and are looking to wager on pandemic stocks post-dip, give this name a look. It's not as strong a contender as Moderna, but it's leaps and bounds ahead of also-rans like iBio and Inovio.However, if you are a more cautious investor, it may pay to take a wait-and-see approach with CureVac stock. Shares could fall to a better entry point in the next few months. But, for now, shares still price-in much of the upside.On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. Thomas Niel, contributor to InvestorPlace, has written single-stock analysis since 2016. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Is CureVac a Buy on the Pullback? It Depends appeared first on InvestorPlace.
German biotech firm, CureVac (NASDAQ:CVAC), has gained some major heat since making its debut in the public market less than two weeks ago. The company saw its shares nearly tripled in value on the first day of trading and CureVac stock rose from $16 per share to $44.Source: Shutterstock The need for a vaccine to combat the virus has put biotech firms like CureVac on the hotlist for many investors. The company was able to raise $213 million at its initial public offering (IPO) on the Nasdaq which boosted its market valuation to $2.8 billion.As progress towards a Covid-19 vaccination continues, CureVac stock remains an attractive biotech investment.InvestorPlace - Stock Market News, Stock Advice & Trading Tips CureVac Stock Gains Big on the NasdaqThe coronavirus has wreaked havoc on economies across the globe and claimed the lives of more than 750,000 people. The development of a vaccine for the virus has thrust, biotech firms like CureVac into the spotlight. * 9 Gold Stocks to Buy That Still Have Room to Run Although CureVac is fairly new to the U.S biotech market, its successful IPO debut has already put the firm ahead of rivals like Novavax (NASDAQ:NVAX) and Inovio Pharmaceuticals (NASDAQ:INO).A major reason for this is because of the company's success with mRNA research. mRNA is a crucial element in developing a cure for the virus because it can generate the antibodies required for the vaccine.In the race to develop a vaccine, investors are willing to put their money behind companies who are able to produce the vaccine quickly and at scale. CureVac's positive results in its Covid vaccine pre-trials generated a lot of interest among investors.In the first phase, the company was able to produce a vaccine that showed promising signs on a much lower dosage (2-6 micrograms) over competitors like Moderna (NASDAQ:MRNA) that was able to achieve the same result on a higher dosage (100 micrograms). This gave the company a competitive edge in the U.S market.Although CureVac has made significant progress towards a vaccine, it still remains marginally behind bigger biotech firms.As of this writing, the company's market cap sits at $11.82 billion but revenues in its most recent quarter were recorded at just $3.1 million. Many investors remain wary of CureVac stock and believe the company is grossly overvalued.However, given the uncertainties that exist in the economic environment and the burgeoning need for a vaccine to combat the pandemic, this biotech stock is worth your investment despite its inflated numbers. Talks of a Covid-19 SupplyAfter its IPO high on August 13, CureVac stock saw a second surge in its share price last Thursday. This bump comes after talks of the company supplying a Covid-19 vaccine to the European Commission (EC). The stock price rose by 9.8% after the announcement was made.While the deal has not been finalized, CureVac is in advanced talks with the Commission to supply 225 million doses of the vaccine to European member states. In addition to this, they will also supply the executive arm of the branch with an additional 180 million doses, bringing the total vaccine count to 405 million.Even if the potential deal goes through, the actual delivery of the vaccines will not take place unless they are fully approved. CureVac is currently in the first phase of its clinical trials and will use mRNA technology to create the final product. The biotech firm expects to get results from this trial at the start of the fourth quarter.CureVac will be able to use the money raised from its IPO to further the development of the vaccine. Franz-Werner Haas, the CEO of CureVac says that the vaccine will have a list price of 10-15 euros and will be available to the public by mid-2021.The EC is also in early talks with GlaxoSmithKline (NYSE:GSK) and Sanofi (NYSE:SNY) for the advance purchase of its vaccines. The Bottom Line on CureVacAs a pioneer of mRNA technology, CureVac is a major contender in the race to develop the Covid vaccine. The company is also backed by Bill and Melinda Gates and received a $356 million investment from the German government for research and development.CureVac may not be as large as biotech leaders like Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) but the company's strong entry into the public market and its history of positive clinical trials show promise for the future. We recommend you stay invested in CureVac and watch its progress on the vaccine from trial to market.Divya Premkumar has a finance degree from the University of Houston, Texas. She is a financial writer and analyst who has written stories on various financial topics from investing to personal finance. Divya has been writing for InvestorPlace since 2020. As of this writing, Divya Premkumar did not own any of the aforementioned stocks. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post CureVac Stock Soars After Talks of Supplying Vaccines for the EU appeared first on InvestorPlace.
After a bit of a late summer breather, news about a Covid-19 vaccine is heating up again as a handful of leading programs move rapidly into a decisive phase.
As, countries in Europe are seeing a resurgence of coronavirus cases, leaving the WHO to issue a warning, and teachers threaten to strike in the United States due to more outbreaks, Johnson and Johnson announced that it will test its vaccine on 60,000 volunteers in September. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
Full Time Employees: 484
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.